#DIA2024 united industry leaders, regulators, and patient advocates to discuss the future of #healthcare, and Tamei Elliott, DIA's Associate Director of Scientific Programs, and Radha Goolabsingh, DIA's Global Regulatory Strategy and Engagement Leader, briefly shared their biggest takeaways from the four-day event. Read more about what they learned and what they expect to happen as a result of the conversations that took place in San Diego.
DIA’s Post
More Relevant Posts
-
NPC Chief Strategy Officer | Kimpossibility Life Coach & Yoga Teacher | Biopharmaceutical & Health Policy Researcher | Public Speaker
ICER’s value assessment methods can systematically undervalue treatments, which may impact patient access to those treatments and the incentives for future innovation. I spoke with AJMC - The American Journal of Managed Care to share three recommendations to improve ICER's approach: https://lnkd.in/eqgzJUnD
Kimberly Westrich's ICER Recommendations to Improve Drug Pricing Data Accuracy
ajmc.com
To view or add a comment, sign in
-
PERIGEE HEALTH - a Market Access Agency | Seasoned Biotech/Healthcare Executive | Market Access Executive | Early Seed & Capital Funding Experience | Board Member
The growing specialty drug market indicates more than a shift in treatment paradigms—it's showing a profound evolution in our approach to healthcare by emphasizing personalized solutions tailored to individual needs and conditions. This trajectory tells us that medical interventions are becoming increasingly targeted, efficient, and, ultimately, more effective. This could potentially offer hope for improved outcomes and quality of life across more diverse patient populations, though the growing market doesn't inherently mean easier access for patients. #MarketAccess #SpecialtyDrugs #RareDiseases
Specialty Drug Market Continues Upward Growth Trend
drugtopics.com
To view or add a comment, sign in
-
Dive into what's in store for #biopharma and #medtech, and what factors could drive innovation in Deloitte's 2024 Health Care and Life Sciences Outlook article. Read it here: https://bit.ly/48cltwL via Deloitte
2024 Outlook for Life Sciences
www2.deloitte.com
To view or add a comment, sign in
-
Check out our latest resource by Suvekshya Aryal, Research Scientist at VivoSense! Discover how we enhance patient-centricity in digital health by navigating regulatory guidance and implementing best practices. Explore solutions that put patients first, ensuring compliance and innovation work together. Read more on our website and join the discussion on developing healthcare! Read the full article here: https://hubs.ly/Q02G0TG-0 #clinicalresearch #clinicaltrials #digitalendpoints #digitalbiomarkers
Enhancing Patient-Centricity in Digital Health: Navigating Regulatory Guidance and Best Practices - Vivosense
vivosense.com
To view or add a comment, sign in
-
Deal Cansino biologics partners with SPIMACO to bring menhycia vaccine for meningococcal disease to saudi arabia and key mena markets ➡ https://lnkd.in/gCWSX9PB Saniona and boehringer ingelheim amend ongoing collaboration, for CNS ion channel target drug candidates in schizophrenia treatment, with research funding ➡https://lnkd.in/g7pyNa6f Genequantum healthcare partners with biomap in strategic collaboration for development of novel ADC candidate, utilizing proprietary conjugation technology platforms ➡https://lnkd.in/gadXPbhQ Clinical Trials Sensorion's phase 2a trial of SENS-401 shows preliminary safety data in hearing disorders induced by cisplatin ➡ https://lnkd.in/ggJJJTaa Invivyd's phase 3 trial of INVYMAB shows high serum virus neutralizing antibody titer levels in immunocompromised participants for prevention of symptomatic COVID-19 ➡ https://lnkd.in/grFZ-XFV
Efortless - BioResearchAI
efortless.bio
To view or add a comment, sign in
-
Missed Dr. Ed LeCluyse's webinar on TruVivo's latest in toxicity testing? Here's a quick overview: - Insights into long-lasting enzymatic activity - Accurate compound toxicity ranking - Enhanced assessments with human Kupffer cells Catch the recording here: https://lnkd.in/e8EMVE5v #WebinarSummary #Toxicology #TruVivo
TruVivo is a Promising New Tool for Toxicity Testing
lnhlifesciences.org
To view or add a comment, sign in
-
📹In this video interview, Chris Dowd, senior vice president of market development, ConnectiveRx, discusses the evolution of drug copay adjustment programs and the circumstances that fueled their controversy across industry, political, and healthcare community circles.
Behind the Push and Pull of Copay Accumulator Programs
pharmexec.com
To view or add a comment, sign in
-
The Healthcare Stage I Episode 8 I Golden Heart Flower's GHF201: Advancing Rare Disease Treatment Episode 8......coming soon This episode is dedicated to a conversation with Yaniv Glazer, The CEO of GHF- Golden Heart Flower, an early-stage Israeli pharmaceutical company dedicated to addressing rare diseases. Specifically, we explore their focus on Adult Polyglucosan Body Disease (APBD) and their development of GHF201, a small molecule drug. GHF201 shows promise beyond APBD, potentially impacting various lysosomal storage diseases by enhancing lysosomal activity. With approval for compassionate use from the Israeli Ministry of Health, the company has gathered 5 years of clinical data from 3 APBD patients, indicating both safety and efficacy. Currently seeking $10M in funding to complete CMC and toxicology studies, inorder to initiate its first clinical study. For pharmaceutical investors interested in the rare disease sector, this podcast offers a sober analysis of the company's progress and investment prospects. #TheHealthcareStage #Pharmaceuticals #RareDiseases #Investors #Healthcare #VC #AdultPolyglucosanBodyDisease #GHF201 #lysosomalStorageDiseases #GlycogenStorageDiseases Shlomo Haim Schneider, Joshua Mincer, MD, PhD, Abigail Livny-Ezer, Idit Lachover- Roth, Nikolai Kunicher, Netta Granot, Hezi Himelfarb, Avishay Sidlesky, Nadav Askari, Ph.D., Masha Zavin, Elad Yakobson, Tommer Nir https://lnkd.in/d-8UK-WT
The Healthcare Stage I Episode 8 I Short
https://www.youtube.com/
To view or add a comment, sign in
-
Highly recommend
The Healthcare Stage I Episode 8 I Golden Heart Flower's GHF201: Advancing Rare Disease Treatment Episode 8......coming soon This episode is dedicated to a conversation with Yaniv Glazer, The CEO of GHF- Golden Heart Flower, an early-stage Israeli pharmaceutical company dedicated to addressing rare diseases. Specifically, we explore their focus on Adult Polyglucosan Body Disease (APBD) and their development of GHF201, a small molecule drug. GHF201 shows promise beyond APBD, potentially impacting various lysosomal storage diseases by enhancing lysosomal activity. With approval for compassionate use from the Israeli Ministry of Health, the company has gathered 5 years of clinical data from 3 APBD patients, indicating both safety and efficacy. Currently seeking $10M in funding to complete CMC and toxicology studies, inorder to initiate its first clinical study. For pharmaceutical investors interested in the rare disease sector, this podcast offers a sober analysis of the company's progress and investment prospects. #TheHealthcareStage #Pharmaceuticals #RareDiseases #Investors #Healthcare #VC #AdultPolyglucosanBodyDisease #GHF201 #lysosomalStorageDiseases #GlycogenStorageDiseases Shlomo Haim Schneider, Joshua Mincer, MD, PhD, Abigail Livny-Ezer, Idit Lachover- Roth, Nikolai Kunicher, Netta Granot, Hezi Himelfarb, Avishay Sidlesky, Nadav Askari, Ph.D., Masha Zavin, Elad Yakobson, Tommer Nir https://lnkd.in/d-8UK-WT
The Healthcare Stage I Episode 8 I Short
https://www.youtube.com/
To view or add a comment, sign in
-
I was so honored to speak at #DIA2024 today as part of the panel “Early Engagement to Enhance the Incorporation of Patient Experience Data in Drug Development Programs and Regulatory Decision-making.“ A big thank you to Steffen Thirstrup and Robyn Bent for organizing and leading the discussion and to Dr Solange Corriol-Rohou, MD, Juan Garcia Burgos, and Maria Apostolaros for fantastic insights and lessons learned. Some of the key take-away for me : - we have come such a long way in patient engagement and patient experience data, in particular for #rarediseases; yet, we have a long way to go. - patient experience data means a lot of different things to a lot of different people, and that diversity of use cases is great, but it can also be really confusing! - patient experience data must be fit for purpose. What that looks like is not always clear though. Standardization through efforts at FDA, European Medicines Agency, and through international bodies like #ICH is really important, and we need to get these guidance documents right. - we now have a LOT of success stories where patient experience data informed study design, endpoint selection, recruitment strategies, informed consent and assent, benefit-risk-consideration, labeling, and so much more. We need to capture these wins and the best practices and approaches that led to success. We also need metrics, measurement, and better transparency in how patient experience data is used to inform #drugdevelopment and #regulatorydecisionmaking - despite all the progress most #raredisease #PFDD meetings and listening sessions still occur too late in the drug development process; we need to disbunk assumptions that these meetings require high production and costly consultants; - we need to talk about the resources and tools needed to support patient experience data collection - for sponsors as well as FDA and patient groups! -we need public-private partnerships and a long view, changing minds and practices will not happen overnight. And we need to keep showing the impact and ROI! What a great discussion! Thank you for including the National Organization for Rare Disorders in this discussion!
To view or add a comment, sign in
37,916 followers